bright minds biosciences inc - DRUG

DRUG

Close Chg Chg %
88.65 1.25 1.41%

Closed Market

89.90

+1.25 (1.41%)

Volume: 115.22K

Last Updated:

Apr 17, 2026, 4:00 PM EDT

Company Overview: bright minds biosciences inc - DRUG

DRUG Key Data

Open

$90.34

Day Range

89.47 - 92.39

52 Week Range

23.18 - 123.75

Market Cap

$867.63M

Shares Outstanding

9.79M

Public Float

N/A

Beta

-5.35

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.94

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

174.77K

 

DRUG Performance

1 Week
 
7.60%
 
1 Month
 
25.52%
 
3 Months
 
2.16%
 
1 Year
 
171.52%
 
5 Years
 
361.40%
 

DRUG Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About bright minds biosciences inc - DRUG

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

DRUG At a Glance

Bright Minds Biosciences, Inc.
400 North Aberdeen Street
Chicago, Illinois 60642
Phone 1-647-407-2515 Revenue 0.00
Industry Biotechnology Net Income -8,746,898.64
Sector Health Technology Employees N/A
Fiscal Year-end 09 / 2026
View SEC Filings

DRUG Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

DRUG Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

DRUG Liquidity

Current Ratio 36.101
Quick Ratio 36.101
Cash Ratio 35.501

DRUG Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -26.834
Return on Equity -27.74
Return on Total Capital -14.811
Return on Invested Capital -27.714

DRUG Capital Structure

Total Debt to Total Equity 0.153
Total Debt to Total Capital 0.153
Total Debt to Total Assets 0.149
Long-Term Debt to Equity 0.05
Long-Term Debt to Total Capital 0.05
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bright Minds Biosciences Inc - DRUG

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
4.73K 53.72K 53.91K 54.98K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.73K 53.72K 53.91K 54.98K
Depreciation
4.73K 53.72K 53.91K 54.98K
Amortization of Intangibles
- - - -
-
COGS Growth
- +1,036.78% +0.36% +1.99%
Gross Income
(4.73K) (53.72K) (53.91K) (54.98K)
Gross Income Growth
- -1,036.78% -0.36% -1.99%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
11.72M 5.41M 2.01M 9.89M
Research & Development
9.53M 3.71M 867.14K 7.93M
Other SG&A
2.18M 1.70M 1.15M 1.96M
SGA Growth
+68.29% -53.84% -62.76% +391.01%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.57K
-
EBIT after Unusual Expense
(11.72M) (5.46M) (2.07M) (9.94M)
Non Operating Income/Expense
9.51K 10.52K 15.30K 1.22M
Non-Operating Interest Income
- - 22.14K 1.09M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 14.64K 6.57K 25.64K
Interest Expense Growth
- - -55.11% +290.10%
-
Gross Interest Expense
- 14.64K 6.57K 25.64K
Interest Capitalized
- - - -
-
Pretax Income
(11.71M) (5.47M) (2.06M) (8.75M)
Pretax Income Growth
-71.24% +53.34% +62.33% -324.81%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(11.71M) (5.47M) (2.06M) (8.75M)
Minority Interest Expense
- - - -
-
Net Income
(11.71M) (5.47M) (2.06M) (8.75M)
Net Income Growth
-71.24% +53.34% +62.33% -324.81%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(11.71M) (5.47M) (2.06M) (8.75M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(11.71M) (5.47M) (2.06M) (8.75M)
EPS (Basic)
-4.7414 -1.4694 -0.4777 -1.2717
EPS (Basic) Growth
-24.41% +69.01% +67.49% -166.21%
Basic Shares Outstanding
2.47M 3.72M 4.31M 6.88M
EPS (Diluted)
-4.7414 -1.4694 -0.4777 -1.2717
EPS (Diluted) Growth
-24.41% +69.01% +67.49% -166.21%
Diluted Shares Outstanding
2.47M 3.72M 4.31M 6.88M
EBITDA
(11.72M) (5.41M) (2.01M) (9.89M)
EBITDA Growth
-68.29% +53.84% +62.76% -391.01%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 146.606
Number of Ratings 7 Current Quarters Estimate -1.305
FY Report Date 06 / 2026 Current Year's Estimate -4.861
Last Quarter’s Earnings -0.862 Median PE on CY Estimate N/A
Year Ago Earnings -1.302 Next Fiscal Year Estimate -8.506
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 6 6 6
Mean Estimate -1.30 -1.79 -4.86 -8.51
High Estimates -0.73 -0.49 -2.80 -0.50
Low Estimate -1.77 -2.85 -6.35 -13.32
Coefficient of Variance -32.68 -49.04 -29.54 -59.45

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 5 6
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Bright Minds Biosciences Inc in the News